Market Overview

Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

Related GALT
Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July
Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company's lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis (NASH) liver disease.

Posted-In: News

 

Most Popular

Related Articles (GALT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free